Juan-manuel M. Sancho

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 06, 2026

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. Cancers 2026, 18, 395.

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. Cancers 2026, 18, 395.

Journal: Cancers

Published: May 28, 2026

Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.

Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.

Journal: Cancers

Published: November 14, 2025

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Journal: British journal of haematology

Published: November 03, 2025

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Journal: Blood advances

Published: September 25, 2025

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma.

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma.

Journal: Blood advances

Published: September 25, 2025

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

Journal: HemaSphere

Published: September 17, 2025

Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy.

Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy.

Journal: Bone marrow transplantation

Published: May 30, 2025

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 01, 2025

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.

Journal: Lancet (London, England)

Published: March 26, 2025

The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential.

The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential.

Journal: Blood advances

Published: February 10, 2025

Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI.

Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI.

Journal: ESMO open

Published: February 05, 2025

Showing 1-12 of 127

Last Updated: 09/26/2026